Siltuximab: all 39 studies that test it
Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple MyelomaRecruitingNCT07106671Phase 2
- A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection After Lung TransplantationRecruitingNCT06990711Phase 1
- A Study of Melphalan With or Without Siltuximab in People With Multiple Myeloma Having an Autologous Stem Cell TransplantRecruitingNCT06679829Phase 2
- Siltuximab for the Prevention of Severe Immune-Related Adverse Events During Immune Checkpoint Inhibitor Rechallenge in Patients With Advanced Cancer, CIRES TrialRecruitingNCT06470971Phase 2
- Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to EpcoritamabRecruitingNCT06447376Phase 1
- Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAMRecruitingNCT05697510Phase 1
- Screening Trial for Pain Relief in Schwannomatosis (STARFISH)RecruitingNCT05684692Phase 2
- Siltuximab in SchizophreniaRecruitingNCT02796859Phase 1/2
- Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell TherapyCompletedNCT04975555Phase 2Results posted
- Treatment of COVID-19 Patients With Anti-interleukin DrugsCompletedNCT04330638Phase 3Results posted
- Siltuximab and Spartalizumab in Patients With Metastatic Pancreatic CancerCompletedNCT04191421Phase 1/2Results posted
- Modulation of STAT3 Signaling With Siltuximab in Type 1 DiabetesCompletedNCT02641522Early Phase 1Results posted
- Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)CompletedNCT01531998Phase 1/2Results posted
- A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic SyndromeTerminatedNCT01513317Phase 2Results posted
- A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple MyelomaCompletedNCT01484275Phase 2Results posted
- A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's DiseaseCompletedNCT01400503Phase 2Results posted
- A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's DiseaseCompletedNCT01024036Phase 2Results posted
- A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma PatientsCompletedNCT00911859Phase 2Results posted
- S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00433446Phase 2Results posted
- A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00401843Phase 2Results posted
- A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)TerminatedNCT00385827Phase 2Results posted
- Siltuximab for Cytokine Release Syndrome Prophylaxis Prior to tx w/ Teclistamab in RRMMWithdrawnNCT06352866Phase 2
- Siltuximab for the Prevention of CAR T Cell Related Cytokine Release Syndrome in Patients With CD19 Positive Non-Hodgkin LymphomaCompletedNCT05665725Phase 1
- Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)TerminatedNCT05316116Early Phase 1
- Siltuximab In Siltuximab-RElapsed/REfractory Multicentric CAstleman DiseaseTerminatedNCT04838860Phase 2
- SILtuximab in Viral ARds (SILVAR) StudyTerminatedNCT04616586Phase 3
- Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 PneumoniaCompletedNCT04329650Phase 2
- Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL AmyloidosisActive, not recruitingNCT03315026Phase 2
- Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia MyelofibrosisWithdrawnNCT02805868Early Phase 1
- A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy ParticipantsCompletedNCT02074800Phase 1
- A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple MyelomaTerminatedNCT01309412Phase 1
- A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaWithdrawnNCT01266811Phase 3
- A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple MyelomaCompletedNCT01219010Phase 1
- A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid TumorsCompletedNCT00841191Phase 1/2
- A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's DiseaseCompletedNCT00412321Phase 1
- An Efficacy and Safety Study of Siltuximab in Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT00402181Phase 2
- A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate CancerCompletedNCT00401765Phase 1
- S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney CancerWithdrawnNCT00311545Phase 2
- A Study of CNTO 328 in Subjects With Metastatic Renal Cell CarcinomaCompletedNCT00265135Phase 1/2